Compare AU
Compare MCCL vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are MCCL and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
MCCL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 10 | 83 |
Median incremental investment | $649.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,900.80 | $1,456.00 |
Average age group | 26 - 35 | > 35 |
Key Summary
MCCL | CURE | |
|---|---|---|
Strategy | MCCL.AX was created on 2022-01-20 by Munro. The fund's investment portfolio concentrates primarily on theme equity. The Fund is to maximise long term capital appreciation, by investing primarily in a concentrated long-only portfolio of companies focused on decarbonisation and climate change located anywhere in the world. The Fund aims to achieve a return greater than the MSCI All Country World (Net) Index in $A (Net) over a 5 to 7 year period | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Munro Climate Change Leaders Fund Active ETF (100 %) | Natera Inc (3.33 %) Incyte Corp (2.96 %) Gilead Sciences Inc (2.80 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.9 % | 0.45 % |
Key Summary
MCCL | CURE | |
|---|---|---|
Issuer | Munro | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.9 % | 0.45 % |
Price | $17.74 | $51.97 |
Size | N/A | $36.301 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.06 % | 4.24 % |
Market | ASX | ASX |
First listed date | 19/01/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MCCL | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 10 | 83 |
Median incremental investment | $649.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,900.80 | $1,456.00 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
MCCL | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
MCCL | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |